

Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021

Patrick M Meyer Sauter¹, Michael L Beeton², Søren A Uldum³, Nathalie Bossuyt⁴, Melissa Vermeulen⁴, Katherine Loens⁵, Sabine Pereyre⁶, Cécile Bébéar⁶, Darja Keše⁷, Jessica Day⁸, Baharak Afshar⁸, Victoria J Chalker⁸, Gilbert Greub⁹, Ran Nir-Paz^{10,11}, Roger Dumke¹², ESGMAC–MyCOVID Study Team¹³

1. Division of Infectious Diseases and Hospital Epidemiology, University Children's Hospital Zurich, Zurich, Switzerland
2. Microbiology and Infection Research Group, Department of Biomedical Sciences, Cardiff Metropolitan University, Cardiff, United Kingdom
3. Department of Bacteria, Parasites and Fungi, Statens Serum Institute, Copenhagen, Denmark
4. Epidemiology of Infectious Diseases, Sciensano, Brussels, Belgium
5. Department of Microbiology, National Reference Centre for Respiratory Pathogens, University Hospital Antwerp, Antwerp, Belgium
6. UMR CNRS 5234, Fundamental Microbiology and Pathogenicity, University of Bordeaux, Bordeaux, France
7. Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
8. Public Health England, London, United Kingdom
9. Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
10. Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
11. Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel
12. TU Dresden, University Hospital Carl Gustav Carus, Institute of Medical Microbiology and Virology, Dresden, Germany
13. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycoplasma and Chlamydia Infections (ESGMAC) "Mycoplasma pneumoniae detections before and during the COVID-19 pandemic (MyCOVID)" Study Team members are listed under collaborators

Correspondence: Patrick M. Meyer Sauter (patrick.meyersauter@kispi.uzh.ch)

Citation style for this article:

Meyer Sauter Patrick M, Beeton Michael L, Uldum Søren A, Bossuyt Nathalie, Vermeulen Melissa, Loens Katherine, Pereyre Sabine, Bébéar Cécile, Keše Darja, Day Jessica, Afshar Baharak, Chalker Victoria J, Greub Gilbert, Nir-Paz Ran, Dumke Roger, ESGMAC–MyCOVID Study Team. Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021. Euro Surveill. 2022;27(19):pii=2100746. <https://doi.org/10.2807/1560-7917.ES.2022.27.19.2100746>

Article submitted on 15 Jul 2021 / accepted on 27 Jan 2022 / published on 12 May 2022

Background: *Mycoplasma pneumoniae* respiratory infections are transmitted by aerosol and droplets in close contact. **Aim:** We investigated global *M. pneumoniae* incidence after implementation of non-pharmaceutical interventions (NPIs) against COVID-19 in March 2020. **Methods:** We surveyed *M. pneumoniae* detections from laboratories and surveillance systems (national or regional) across the world from 1 April 2020 to 31 March 2021 and compared them with cases from corresponding months between 2017 and 2020. Macrolide-resistant *M. pneumoniae* (MRMp) data were collected from 1 April 2017 to 31 March 2021. **Results:** Thirty-seven sites from 21 countries in Europe, Asia, America and Oceania submitted valid datasets (631,104 tests). Among the 30,617 *M. pneumoniae* detections, 62.39% were based on direct test methods (predominantly PCR), 34.24% on a combination of PCR and serology (no distinction between methods) and 3.37% on serology alone (only IgM considered). In all countries, *M. pneumoniae* incidence by direct test methods declined significantly after implementation of NPIs with a mean of 1.69% (SD ±3.30) compared with 8.61% (SD ±10.62) in previous years ($p < 0.01$). Detection rates decreased with direct but not with indirect test methods (serology) (−93.51% vs +18.08%; $p < 0.01$). Direct detections remained low worldwide throughout April 2020 to March 2021 despite widely

differing lockdown or school closure periods. Seven sites (Europe, Asia and America) reported MRMp detections in one of 22 investigated cases in April 2020 to March 2021 and 176 of 762 (23.10%) in previous years ($p = 0.04$). **Conclusions:** This comprehensive collection of *M. pneumoniae* detections worldwide shows correlation between COVID-19 NPIs and significantly reduced detection numbers.

Introduction

Non-pharmaceutical interventions (NPIs) were suggested to reduce the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the worldwide coronavirus disease (COVID-19) pandemic [1]. Many countries introduced NPIs in March 2020, which included physical distancing measures, personal protective measures (e.g. the use of masks, improved hand hygiene, respiratory etiquette), stay-at-home orders, school and day-care closures, closing borders and travel restrictions. The NPIs have been temporally associated with a global unprecedented suppression of influenza epidemics and other viral respiratory infections, such as respiratory syncytial virus (RSV) [2-8]. COVID-19 vaccinations were available as measures in addition to NPIs since December 2020 [9].

TABLE 1A

 Demographic characteristics and laboratory information of participating sites, by United Nations (UN) region, global survey of *Mycoplasma pneumoniae* detections, April 2017–March 2021

UN region and country	City or region	National pandemic lockdown (days, period) ^a	School closure duration (days) ^b	Laboratory and/or system ^c	Test method (technique; product)	Company or reference	Macrolide resistance determination
Europe							
Western Europe							
France	Bordeaux	102 days (17 Mar–11 May 2020; 28 Oct–14 Dec 2020)	43	Hospital / clinical laboratory (tertiary centre)	NAAT (PCR, real-time; in-house)	[47]	Yes [48]
Switzerland	Geneva	41 days (16 Mar–26 Apr 2020)	31	Hospital / clinical laboratory (tertiary centre)	NAAT (multiplex PCR, real-time; BioGX Sample-Ready BD MAX System)	BD Diagnostics	No
	Lausanne			Hospital / clinical laboratory (secondary centre)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel)	bioMérieux/BioFire Diagnostics	No
	Bern ^d			Hospital / clinical laboratory (tertiary centre)	NAAT (multiplex PCR, real-time; Anyplex II RB5 Detection)	Seegene Inc.	No
	Lucerne ^d			Hospital / clinical laboratory (tertiary centre)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel)	bioMérieux/BioFire Diagnostics	No
	Bellinzona			Surveillance system (regional; 0.4 million population)^e	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel) ^f	bioMérieux/BioFire Diagnostics	No
	Zurich (A)			Hospital / clinical laboratory (tertiary centre)	NAAT (PCR, real-time; in-house)	[49]	Yes [50]
	Zurich (B) ^d			Hospital / clinical laboratory (tertiary centre)	NAAT (PCR, real-time; in-house) ^g	[49]	Yes [50]
	St. Gallen ^d			Hospital / clinical laboratory (tertiary centre)	NAAT (multiplex PCR, real-time; Allplex Respiratory Panel)	Seegene Inc.	No
	Aarau			Hospital / clinical laboratory (tertiary centre)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel) ELISA ^h (ImmunoWELL Mycoplasma IgM/IgG)	bioMérieux/BioFire Diagnostics Thermo Fisher Scientific Remel Inc.	No
	Basel (A)			Hospital / clinical laboratory (tertiary centre)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel)	bioMérieux/BioFire Diagnostics	No
Basel (B) ^d	Hospital / clinical laboratory (tertiary centre)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel) ⁱ	bioMérieux/BioFire Diagnostics	No			
Germany	Homburg	161 days (17 Mar–5 May 2020; 19 Dec 2020–end of survey period)	92	Hospital / clinical laboratory (tertiary centre)	NAAT (multiplex PCR, real-time; AID CAP Bac PCR Kit) CLIA ^a (<i>Mycoplasma pneumoniae</i> Virclia IgM/IgG Monotest)	Autoimmun Diagnostika GmbH (AID) Vircell, S.L.	No
	Düsseldorf			Hospital / clinical laboratory (tertiary centre)	NAAT (PCR, real-time; in-house) ELISA ^h (EIA Mycoplasma IgM/IgG/IgA)	[51] DIAsource ImmunoAssays SA	No
				Saxony ^j	Surveillance system (regional; 4.1 million population)^k	Combination of direct and indirect test methods (different techniques) ^k	[12]

CLIA: chemiluminescent immunoassay; ELISA: enzyme-linked immunosorbent assay; Ig, immunoglobulin; NA: not available; NAAT: nucleic acid amplification test; SAL: silver amplification immunochromatography; UN: United Nations.

^a Stay-at-home orders for the general population (referred to as lockdown) according to an ECDC document [25] for Europe and to Wikipedia [26] for other UN regions, with adjustments made by the local participating author and considered until the end of the study period (31 March 2021).

^b Full and partial school closure duration in days according to [27] until 2 March 2021 (last update before end of study period).

^c More detailed information including reporting characteristics, de-duplication and exclusion criteria are provided in Supplementary Table S2.

^d ≥90% of data are from children and adolescents <18 years of age.

^e Data from several hospitals in the region of Ticino.

^f Additional use of a specific in-house PCR [52].

^g From 12 October 2020 to the end of the survey period additional testing with the FilmArray Respiratory Panel (bioMérieux/BioFire Diagnostics).

^h In addition to PCR also serological data separately reported.

ⁱ Multiplex PCR testing before 2020 using the Respifinder (Pathofinder), and single PCR testing over the total survey period with a specific in-house PCR, as described previously [61].

^j Exclusively positive test numbers (and no total test numbers) available and/or reported.

^k Data from the federal state of Saxony detected by the Landesuntersuchungsanstalt Sachsen based on combined direct and indirect test methods, but predominantly on serology (no information on isotypes) [12].

TABLE 1B
Demographic characteristics and laboratory information of participating sites, by United Nations (UN) region, global survey of *Mycoplasma pneumoniae* detections, April 2017–March 2021

UN region and country	City or region	National pandemic lockdown (days, period) ^a	School closure duration (days) ^b	Laboratory and/or system ^c	Test method (technique; product)	Company or reference	Macrolide resistance determination
Belgium	Antwerp, Leuven (national reference laboratory)	52 days (18 Mar–9 May 2020)	76	Hospital / clinical laboratory (tertiary centre) and national reference laboratory ^d	NAAT (PCR, real-time; in-house)	[52]	Yes [48]
	National surveillance ^e			Surveillance system (national; 60% of all Belgian microbiology laboratories) ^m	Direct test methods (different techniques) ⁿ	[53]	No
The Netherlands	Rotterdam	99 days (16 Mar–6 Apr 2020; 15 Dec 2020–2 Mar 2021)	74	Hospital / clinical laboratory (tertiary centre)	NAAT (PCR, real-time; in-house)	[54]	No
Northern Europe							
England	National reference laboratory ⁿ	72 days (14 Mar–9 May 2020; 5 Nov–1 Dec 2020)	102	National reference laboratory	NAAT (multiplex PCR, real-time; in-house)	[20]	Yes [55]
Denmark	National surveillance	99 days (12 Mar–13 Apr 2020; 25 Dec–1 Mar 2020)	76	Surveillance system (national; 5.8 million population)	NAAT (PCR, different techniques) ^o	[56]	No
Finland	Turku	98 days (16 Mar–22 Jun 2020)	42	Hospital / clinical laboratory (tertiary centre)	Combination of direct and indirect test methods (different techniques) ^p	[57]	No
	National surveillance ^e			Surveillance system (national; 5.5 million population)	Combination of direct and indirect test methods (different techniques) ^q	[6]	No
Norway	Trondheim	81 days (12 Mar–1 Jun 2020)	32	Hospital / clinical laboratory (tertiary centre)	NAAT (multiplex PCR, real-time; in-house)	NA	No
Southern Europe							
Portugal	Coimbra ^d	103 days (19 Mar–2 May 2020; 15 Jan–15 Mar 2021)	67	Hospital / clinical laboratory (tertiary centre)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel)	bioMérieux/BioFire Diagnostics	No
Greece	Athens (A) ^d	179 days (23 Mar–4 May 2020; 7 Nov 2020–22 Mar 2021)	114	Hospital / clinical laboratory (tertiary centre)	ELISA (DRG <i>Mycoplasma pneumoniae</i> ELISA IgM/IgG)	DRG International, Inc.	No
	Athens (B) ^d			Hospital / clinical laboratory (tertiary centre)	ELISA (NovaLisa <i>Mycoplasma pneumoniae</i> IgM/IgG)	Novatec Immundiagnostica GmbH	No
Slovenia	Ljubljana	46 days (19 Mar–4 May 2020)	46	Hospital / clinical laboratory (tertiary centre)	NAAT (multiplex PCR, real-time; Chla/Myco pneumo R-GENE)	bioMérieux/ARGENE	No

CLIA: chemiluminescent immunoassay; ELISA: enzyme-linked immunosorbent assay; Ig, immunoglobulin; NA: not available; NAAT: nucleic acid amplification test; SAI: silver amplification immunochromatography; UN: United Nations.

^a Stay-at-home orders for the general population (referred to as lockdown) according to an ECDC document [25] for Europe and to Wikipedia [26] for other UN regions, with adjustments made by the local participating author and considered until the end of the study period (31 March 2021).

^b Full and partial school closure duration in days according to [27] until 2 March 2021 (last update before end of study period).

^c More detailed information including reporting characteristics, de-duplication and exclusion criteria are provided in Supplementary Table S2.

^d In addition to PCR also serological data separately reported.

^e Multiplex PCR testing before 2020 using the Respifinder (Pathofinder), and single PCR testing over the total survey period with a specific in-house PCR, as described previously [61].

^f Exclusively positive test numbers (and no total test numbers) available and/or reported.

^g Data from the federal state of Saxony detected by the Landesuntersuchungsanstalt Sachsen based on combined direct and indirect test methods, but predominantly on serology (no information on isotypes) [12].

^h National reference laboratory data from the two related hospitals (Antwerp, Leuven; 86–98%) and across the country (2–14%).

^m Data collected through the Belgian Sentinel Network of Laboratories (SNL), a network of ca 95 microbiology laboratories (i.e. 60% of all Belgian microbiology laboratories) [53], based on direct test methods such as NAAT, antigen test, culture, microscopy, 'unknown' or 'other' (cases based on serology were excluded).

ⁿ Period of enhanced surveillance from 1 October 2019 to 30 March 2020.

^o Different PCR assays, of which some are published [56] or commercial kits, but most are unpublished but validated in-house assays.

^p Predominantly by serology (ca 75%; no information on isotypes), partly by multiplex PCR (Allplex Respiratory Panel, Seegene Inc.; ca 25%).

^q Predominantly by PCR.

TABLE 1C

Demographic characteristics and laboratory information of participating sites, by United Nations (UN) region, global survey of *Mycoplasma pneumoniae* detections, April 2017–March 2021

UN region and country	City or region	National pandemic lockdown (days, period) ^a	School closure duration (days) ^b	Laboratory and/or system ^c	Test method (technique; product)	Company or reference	Macrolide resistance determination
Asia							
Western Asia							
Israel	Jerusalem	52 days (12 Mar–3 May 2020)	139	Hospital / clinical laboratory (tertiary centre)	NAAT (PCR, real-time; in-house)	[20]	No
Eastern Asia							
Japan	Kurashiki City (Okayama) ^d	0 days (no national lockdown)	51	Hospital / clinical laboratory (tertiary centre)	NAAT (PCR, real-time; in-house)	[58]	Yes [58]
	Tokyo			Hospital / clinical laboratory (secondary centre)	Rapid antigen test (SAL; FUJI DRI-CHEM IMMUNO AG)	Fujifilm, Kanagawa, Japan	No
Taiwan	Taoyuan ^d	0 days (no national lockdown)	0 (no official school closures)	Hospital / clinical laboratory (tertiary centre)	NAAT (PCR, real-time; in-house)	[59]	Yes [59]
South-eastern Asia							
Singapore	Singapore ^d	55 days (7 Apr–1 Jun 2020)	57	Hospital / clinical laboratory (tertiary centre)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel)	bioMérieux/BioFire Diagnostics	No
South Asia							
India	New Delhi	74 days (25 Mar–7 Jun 2020)	235	Hospital / clinical laboratory (tertiary centre)	ELISA (NovaLis <i>Mycoplasma pneumoniae</i> IgM)	Novatec Immundiagnostica GmbH	NO
America							
Northern America							
United States	Chicago ^d	70 days (21 Mar–30 May 2020)	192	Hospital / clinical laboratory (tertiary centre)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel)	bioMérieux/BioFire Diagnostics	No
Caribbean							
Cuba	National surveillance	240 days (20 Mar–18 Jun 2020; 1 Nov 2020–end of survey period)	121	Surveillance system (national; 11.3 million population)	NAAT (PCR, real-time; in-house)	[60]	Yes [60]
Oceania							
Australia	Darlinghurst (Sydney)	53 days (23 Mar–15 May 2020)	125	Hospital / clinical laboratory (tertiary centre)	NAAT (PCR, real-time; EasyScreen Respiratory Pathogen Detection Kit)	Genetic Signatures	No
New Zealand	Auckland	78 days (national: 23 Mar–13 May 2020; Auckland: 12–18 Aug 2020; 15–17 Feb 2021; 28 Feb–7 Mar 2021)	40	Hospital / clinical laboratory (tertiary centre)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel) ^r	bioMérieux/BioFire Diagnostics	No

CLIA: chemiluminescent immunoassay; ELISA: enzyme-linked immunosorbent assay; Ig, immunoglobulin; NA: not available; NAAT: nucleic acid amplification test; SAL: silver amplification immunochromatography; UN: United Nations.

^a Stay-at-home orders for the general population (referred to as lockdown) according to an ECDC document [25] for Europe and to Wikipedia [26] for other UN regions, with adjustments made by the local participating author and considered until the end of the study period (31 March 2021).


^b Full and partial school closure duration in days according to [27] until 2 March 2021 (last update before end of study period).

^c More detailed information including reporting characteristics, de-duplication and exclusion criteria are provided in Supplementary Table S2.

^d In addition to PCR also serological data separately reported.

FIGURE 1

Study profile, global survey of *Mycoplasma pneumoniae* detections, April 2017–March 2021



UN: United Nations.

^a Three sites provided serological data in addition to PCR.

^b No distinction possible between detection methods, but predominantly serological data included.

Data from some countries during the first months in 2020 indicated that the introduction of NPIs also coincided with a reduction in *Mycoplasma pneumoniae* detections [2,6,10]. *Mycoplasma pneumoniae* is a major bacterial cause of respiratory tract infections in children and adults [11]. These infections occur both endemically in many different climates across the world and epidemically every few years. Previous epidemics in Europe were reported in 2010–2012, 2014–2015 and 2015–2017 [12–15]. *Mycoplasma pneumoniae* is transmitted by aerosol particles and respiratory droplets through close contacts within families, schools, military bases, institutions (residential care and nursing homes, homes for cognitively disabled people etc.) and among closed communities [15–17].

Diagnostic tests for *M. pneumoniae* include nucleic acid amplification tests (NAAT) such as PCR, antigen tests and culture from respiratory specimens (direct test methods) or serology (indirect test method) with varying sensitivities and specificities [11,18,19]. Real-time PCR applications are the most commonly used approach for detection of *M. pneumoniae* in clinical settings [20]. However, real-time PCR is not yet

standardised across laboratories [20], and there are no internationally defined guidelines on the requirements for *M. pneumoniae* testing and surveillance [14]. Some countries collect laboratory reports on *M. pneumoniae* detections through national reference laboratories (e.g. England), but only few countries have a national surveillance (e.g. Denmark) [14]. To our knowledge, no analysis on the *M. pneumoniae* incidence from several United Nations (UN) regions has been published so far.

In this study, we used survey data on laboratory *M. pneumoniae* testing and detection before and during the COVID-19 pandemic across the world to assess the impact of NPIs on the global incidence of *M. pneumoniae* in the first year after the implementation of NPIs. Of particular interest was the impact of children returning to schools on *M. pneumoniae* incidence while maintaining other NPIs during the course of the pandemic, as children are believed to be the main drivers of *M. pneumoniae* transmission [16] and have greater difficulty adhering to physical distancing and personal protective measures. In this context, was also analysed the proportion of females in particular because of their assumed closer vicinity with children.

Methods


Study design

Survey development

A structured survey was developed by a group of members from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), according to guidelines for survey research [21,22]. The survey consisted of six items, covering (i) details of the survey participant, (ii) information on laboratory and area, (iii) local information on stay-at-home orders and school closures during the first year of the pandemic, (iv) detailed information on the test method for *M. pneumoniae* detection (technique, product and company or reference), (v) *M. pneumoniae* test numbers (total tests, positive tests, positive tests by month, proportion of children/adolescents younger than 18 years and of females of any age) for the first 12-month period after the worldwide implementation of NPIs (1 April 2020 to 31 March 2021) and for the same period in the preceding 3 years (1 April 2017 to 31 March 2020), and (vi) macrolide-resistant *M. pneumoniae* (MRMp) testing and detection during the same periods. The survey was only administered in English and built in the SurveyMonkey online survey platform [23]. A pilot test was performed with 10 individuals (infectious diseases specialists and microbiologists) to ensure that the questions were understood and interpreted consistently and that collection of requested data was feasible within the survey time period. Details of the survey are shown in Supplementary Table S1.

FIGURE 2

Global detection of *Mycoplasma pneumoniae*, April 2017–March 2021 (n = 30,617)



Ig: immunoglobulin.

Data from combined serology and PCR tests are shown under indirect test methods (no distinction possible between detection methods, but predominantly serology; Table 1). For serology, only total test numbers of IgM considered. The grey backgrounds indicate the presence of non-pharmaceutical interventions during the COVID-19 pandemic. Detailed graphs separately for each site and country with corresponding local lockdown periods are shown in Supplementary Figures S1–S6.

TABLE 2A

Mycoplasma pneumoniae testing and detection rates per year, April 2017–March 2021 (n = 631,104)

UN region and country	City or region	Test method	April 2017–March 2018			April 2018–March 2019			April 2019–March 2020			April 2020–March 2021 (COVID-19 pandemic)			Difference in detection rate (%) pre-pandemic vs COVID-19 pandemic ^a	P ^b
			Total tests	Positive tests	Detection rate	Total tests	Positive tests	Detection rate	Total tests	Positive tests	Detection rate	Total tests	Positive test	Detection rate		
			(N)	(n)	(%)	(N)	(n)	(%)	(N)	(n)	(%)	(N)	(n)	(%)		
Europe																
Western Europe																
France	Bordeaux	PCR	619	16	2.58	625	22	3.52	530	41	7.74	466	4	0.86	-80.72	<0.01
Switzerland	Geneva	PCR	1,347	30	2.23	1,622	76	4.69	2,119	76	3.59	1,193	7	0.59	-83.60	<0.01
	Lausanne	PCR	388	6	1.55	406	4	0.99	592	20	3.38	246	0	0.00	-100.00	0.02
	Bern ^c	PCR	134	17	12.69	175	43	24.57	191	29	15.18	41	0	0.00	-100.00	<0.01
	Lucerne ^c	PCR	NA	7	NA	229	10	4.37	215	21	9.77	129	1	0.78	-88.90	<0.01
	Bellinzona	PCR	701	10	1.43	1,104	76	6.88	1,540	43	2.79	804	0	0.00	-100.00	<0.01
	Zurich (A)	PCR	1,067	17	1.59	1,361	41	3.01	1,620	50	3.09	1,823	11	0.60	-77.38	<0.01
	Zurich (B) ^c	PCR	104	21	20.19	123	22	17.89	201	54	26.87	1,659	6	0.36	-98.40	<0.01
	St. Gallen ^c	PCR	20	7	35.00	18	5	27.78	19	6	31.58	8	1	12.50	-60.42	0.42
	Aarau	PCR	1,431	36	2.52	1,586	55	3.47	1,955	77	3.94	1,601	10	0.62	-81.51	<0.01
		IgM ELISA	220	14	6.36	229	19	8.30	191	23	12.04	183	13	7.10	-18.81	0.55
IgG ELISA		220	43	19.55	229	50	21.83	191	48	25.13	183	46	25.14	+14.10	0.37	
Basel (A)	PCR	1,535	9	0.59	2,212	12	0.54	5,028	53	1.05	3,061	2	0.07	-92.25	<0.01	
Basel (B) ^c	PCR	870	10	1.15	845	6	0.71	1,050	19	1.81	634	6	0.95	-25.24	0.69	
Germany	Homburg	PCR	2,321	10	0.43	2,395	19	0.79	2,773	17	0.61	2,570	1	0.04	-93.67	<0.01
		IgM ELISA	486	67	13.79	492	70	14.23	544	71	13.05	588	70	11.90	-12.89	0.31
		IgG ELISA	486	277	57.00	492	291	59.15	544	341	62.68	588	331	56.29	-5.75	0.15
	Düsseldorf	PCR	1,515	27	1.78	1,530	18	1.18	1,283	16	1.25	1,011	12	1.19	-15.79	0.65
		IgM ELISA	398	18	4.52	446	78	17.49	585	148	25.30	538	134	24.91	+45.87	<0.01
		IgG ELISA	530	298	56.23	491	288	58.66	561	307	54.72	522	315	60.34	+6.90	0.13
		IgA ELISA ^d	NA	NA	NA	241	95	39.42	560	195	34.82	521	142	27.26	-24.72	<0.01
	Saxony	PCR or serology ^e	NA	2,013	NA	NA	1,044	NA	NA	927	NA	NA	303	NA	NA	NA
Belgium	Antwerp, Leuven (national reference laboratory)	PCR	2,698	30	1.11	1,150	15	1.30	1220	32	2.62	864	3	0.35	-77.15	<0.01
	National surveillance	Direct test methods (different techniques)	NA	1,151	NA	NA	548	NA	NA	833	NA	NA	230	NA	NA	NA
The Netherlands	Rotterdam	PCR	NA	NA	NA	240	36	15.00	407	56	13.76	444	36	8.11	-42.98	<0.01
Northern Europe																
England	National reference laboratory ^f	PCR	138	19	13.77	110	11	10.00	263	118	44.87	155	10	6.45	-77.72	<0.01
Denmark	National surveillance	PCR	100,257	5,303	5.29	80,965	1,371	1.69	100,879	4,383	4.34	58,716	177	0.30	-92.31	<0.01
Finland	Turku	PCR or serology ^e	NA	NA	NA	NA	NA	NA	5,413	211	3.90	3,462	70	2.02	-48.13	<0.01
	National surveillance	PCR or serology ^e	NA	2,420	NA	NA	1,728	NA	NA	1,312	NA	NA	455	NA	NA	NA

COVID-19: coronavirus disease; ELISA: enzyme-linked immunosorbent assay; Ig: immunoglobulin; NA: not available; UN: United Nations.

^a Difference in detection rate between April 2017 and March 2020 (mean positive/total tests across the 3 years) and between April 2020 and March 2021 (absolute number positive/total tests). Percentages showing a reduction in detection rate are indicated in bold.

^b Proportions of positive/total tests from April 2020 to March 2021 were compared with total numbers from April 2017 to March 2020 by Fisher's exact test. p values <0.05 are indicated in bold.

^c >90% of data are from children and adolescents <18 years of age.

^d IgA ELISA introduced in November 2018.

^e Data from combined serology and PCR tests (no distinction possible between detection methods; Table 1).

Entries in italics signify serological data (≠PCR).

TABLE 2B

Mycoplasma pneumoniae testing and detection rates per year, April 2017–March 2021 (n = 631,104)

UN region and country	City or region	Test method	April 2017–March 2018			April 2018–March 2019			April 2019–March 2020			April 2020–March 2021 (COVID-19 pandemic)			Difference in detection rate (%) pre-pandemic vs COVID-19 pandemic ^a	P ^b
			Total tests	Positive tests	Detection rate	Total tests	Positive tests	Detection rate	Total tests	Positive tests	Detection rate	Total tests	Positive test	Detection rate		
			(N)	(n)	(%)	(N)	(n)	(%)	(N)	(n)	(%)	(N)	(n)	(%)		
Norway	Trondheim	PCR	3,306	230	6.96	2,330	56	2.40	2,014	48	2.38	1,263	0	0.00	-100.00	<0.01
Southern Europe																
Portugal	Coimbra ^c	PCR	803	5	0.62	924	90	9.74	1,084	19	1.75	161	0	0.00	-100.00	<0.01
Greece	Athens (A) ^c	IgM ELISA	212	19	8.96	236	51	21.61	250	65	26.00	167	35	20.96	+8.36	0.66
		IgG ELISA	212	44	20.75	236	29	12.29	250	37	14.80	167	41	24.55	+55.79	<0.01
	Athens (B) ^c	IgM ELISA	185	9	4.86	181	15	8.29	231	27	11.69	172	14	8.14	-4.72	1.00
		IgG ELISA	185	59	31.89	181	88	48.62	231	92	39.83	172	44	25.58	-36.10	<0.01
Slovenia	Ljubljana	PCR	1,604	22	1.37	1,887	153	8.11	2,639	495	18.76	1,241	20	1.61	-85.26	<0.01
Asia																
Western Asia																
Israel	Jerusalem	PCR	1,364	45	3.30	1,299	62	4.77	1,637	53	3.24	666	0	0.00	-100.00	<0.01
Eastern Asia																
Japan	Kurashiki City (Okayama) ^c	PCR	30	4	13.33	64	14	21.88	34	3	8.82	5	0	0.00	-100.00	1.00
	Tokyo ^d	Rapid antigen test	346	56	16.18	140	36	25.71	600	36	6.00	120	4	3.33	-71.72	<0.01
Taiwan	Taoyuan ^c	PCR	116	20	17.24	159	63	39.62	204	131	64.22	44	5	11.36	-74.56	<0.01
South-eastern Asia																
Singapore	Singapore ^c	PCR	4,212	387	9.19	8,765	307	3.50	15,860	613	3.87	8,835	33	0.37	-91.76	<0.01
South Asia																
India	New Delhi	IgM ELISA	245	19	7.76	320	18	5.63	205	19	9.27	153	16	10.46	+43.79	0.19
America																
Northern America																
United States	Chicago ^c	PCR	4,221	10	0.24	4,199	25	0.60	4,990	42	0.84	1,695	2	0.12	-79.45	0.01
Caribbean																
Cuba	National surveillance	PCR	902	18	2.00	62	4	6.45	844	20	2.37	4	0	0.00	-100.00	1.00
Oceania																
Australia	Darlinghurst (Sydney)	PCR	15,751	60	0.38	12,187	55	0.45	21,086	168	0.80	70,807	19	0.03	-95.35	<0.01
New Zealand	Auckland	PCR	543	21	3.87	993	26	2.62	858	41	4.78	2,723	4	0.15	-96.00	<0.01
Total (global, participating countries) ^e		Direct test methods (PCR or rapid antigen test considered only)	148,343	6,453	4.35	129,705	2,733	2.11	173,735	6,780	3.90	162,989	374	0.23	-93.51	<0.01
		Indirect test methods (IgM considered only)	1,746	146	8.36	1,904	251	13.18	2,006	353	17.60	1,801	282	15.66	+18.08	0.01

COVID-19: coronavirus disease; ELISA: enzyme-linked immunosorbent assay; Ig: immunoglobulin; NA: not available; UN: United Nations.

^a ≥90% of data are from children and adolescents <18 years of age.

^b IgA ELISA introduced in November 2018.

^c Data from combined serology and PCR tests (no distinction possible between detection methods; Table 1).

^d Period of enhanced surveillance from 1 October 2019 to 30 March 2020.

^e These numbers include only data from PCR or rapid antigen test (for direct test methods) and IgM serology (for indirect test methods).

Entries in italics signify serological data (±PCR).

TABLE 3A

Mycoplasma pneumoniae testing and detection in children/adolescents and females per year, April 2017–March 2021 (n = 154,241 children/adolescents and 285,238 females)

UN region and country	City or region	Test method	April 2017–March 2018						April 2018–March 2019						April 2019–March 2020						April 2020–March 2021 (COVID-19 pandemic)					
			Children/adolescents			Females			Children/adolescents			Females			Children/adolescents			Females			Children/adolescents			Females		
			N	n	%	N	n	%	N	n	%	N	n	%	N	n	%	N	n	%	N	n	%	N	n	%
Europe																										
Western Europe																										
France	Bordeaux	PCR	335	9	2.69	236	11	4.66	282	15	5.32	280	11	3.93	272	28	10.29	248	17	6.85	220	2	0.91	193	0	0.00
Switzerland	Geneva	PCR	201	8	3.98	579	17	2.94	301	43	14.29	704	39	5.54	354	45	12.71	392	34	8.67	161	2	1.24	449	3	0.67
	Lausanne	PCR	42	1	2.38	226	5	2.21	18	1	5.56	200	1	0.50	36	4	11.11	325	9	2.77	2	0	0.00	123	0	0.00
	Bern ^a	PCR	134	17	12.69	65	8	12.31	175	43	24.57	74	18	24.32	191	29	15.18	78	14	17.95	41	0	0.00	16	0	0.00
	Lucerne ^a	PCR	NA	7	NA	NA	3	NA	229	10	4.37	NA	3	NA	215	21	9.77	NA	5	NA	129	1	0.78	NA	1	NA
	Bellinzona	PCR	155	6	3.87	315	2	0.63	471	66	14.01	500	41	8.20	354	22	6.21	661	19	2.87	118	0	0.00	328	0	0.00
	Zurich (A)	PCR	29	2	6.90	NA			43	6	13.95	NA			44	8	18.18	NA			35	1	2.86	NA		
	Zurich (B) ^a	PCR	104	21	20.19	NA			123	22	17.89	NA			201	54	26.87	NA			1,659	6	0.36	NA		
	St. Gallen ^a	PCR	20	7	35.00	14	4	28.57	18	5	27.78	12	5	41.67	19	6	31.58	7	3	42.86	8	1	12.50	4	1	25.00
	Aarau	PCR	441	13	2.95	603	14	2.32	392	22	5.61	723	24	3.32	484	26	5.37	891	38	4.26	287	4	1.39	658	6	0.91
		<i>IgM ELISA</i>	25	4	16.00	91	10	10.99	20	8	40.00	99	7	7.07	33	8	24.24	77	10	12.99	16	3	18.75	69	9	13.04
		<i>IgG ELISA</i>	25	3	12.00	91	15	16.48	20	6	30.00	99	19	19.19	33	9	27.27	77	15	19.48	16	1 ^b	6.25	69	18	26.09
	Basel (A)	PCR	4	0	0.00	644	6	0.93	5	0	0.00	937	7	0.75	9	0	0.00	2,201	25	1.14	1	0	0.00	1,251	2	0.16
Basel (B) ^a	PCR	863	10	1.16	404	5	1.24	845	6	0.71	NA	1	NA	1,050	19	1.81	NA	NA	NA	634	6	0.95	NA	NA	NA	
Germany	Homburg	PCR	53	2	3.77	NA	4	NA	75	3	4.00	NA	8	NA	111	4	3.60	NA	7	NA	88	0	0.00	NA	1	NA
		<i>IgM ELISA</i>	NA			NA			NA			NA			NA			NA			NA					
		<i>IgG ELISA</i>	NA			NA			NA			NA			NA			NA			NA					
	Düsseldorf	PCR	1,003	21	2.09	618	10	1.62	1,026	16	1.56	649	5	0.77	882	15	1.70	523	6	1.15	621	10	1.61	471	4	0.85
		<i>IgM ELISA</i>	264	12	4.55	179	9	5.03	246	36	14.63	173	24	13.87	246	52	21.14	182	37	20.33	253	47	18.58	161	29	18.01
		<i>IgG ELISA</i>	307	168	54.72	237	142	59.92	255	141	55.29	187	118	63.10	226	98	43.36	174	96	55.17	238	132	55.46	157	103 ^b	65.61
		<i>IgA ELISA</i>	NA			NA			120	36	30.00	80	26	32.50	226	37	16.37	174	46	26.44	237	17 ^b	7.17	156	24	15.38
Saxony	<i>PCR or serology</i>	NA			NA			NA			NA			NA			NA			NA			NA			
Belgium	Antwerp, Leuven (national reference laboratory)	PCR	748	16	2.14	1,132	17	1.50	208	4	1.92	486	9	1.85	240	15	6.25	510	17	3.33	100	2	2.00	356	0	0.00
	National surveillance	Direct test methods (different techniques)	NA	740	NA	NA	639	NA	NA	362	NA	NA	285	NA	NA	493	NA	NA	433	NA	NA	86 ^b	NA	NA	140 ^b	NA
The Netherlands	Rotterdam	PCR	NA			NA			47	11	23.40	119	22	18.49	89	26	29.21	163	23	14.11	54	12	22.22	176	19	10.80
Northern Europe																										
England	National reference laboratory	PCR	39	8	20.51	63	7	11.11	34	2	5.88	45	9	20.00	84	51	60.71	102	50	49.02	58	7	12.07	49	5	10.20

COVID-19: coronavirus disease; ELISA: enzyme-linked immunosorbent assay; Ig: immunoglobulin; NA: not available; UN: United Nations.

^a ≥90% of data are from children and adolescents <18 years of age.

^b Statistically significant difference in proportions of children/adolescents or females with positive tests between April 2020 and March 2021 and between April 2017 and March 2020 (Fisher's exact test, $p < 0.05$).

For serology only total test numbers of IgM considered. Entries in italics signify serological data (±PCR).

TABLE 3B

Mycoplasma pneumoniae testing and detection in children/adolescents and females per year, April 2017–March 2021 (n = 154,241 children/adolescents and 285,238 females)

UN region and country	City or region	Test method	April 2017–March 2018						April 2018–March 2019						April 2019–March 2020						April 2020–March 2021 (COVID-19 pandemic)					
			Children/adolescents			Females			Children/adolescents			Females			Children/adolescents			Females			Children/adolescents			Females		
			N	n	%	N	n	%	N	n	%	N	n	%	N	n	%	N	n	%	N	n	%	N	n	%
Denmark	National surveillance	PCR	15,879	2,374	14.95	55,874	2,843	5.09	9,121	515	5.65	44,132	768	1.74	14,307	1,854	12.96	55,356	2,374	4.29	2,650	68	2.57	27,693	83	0.30
Finland	Turku	<i>PCR or serology</i>	NA			NA			NA			NA			1,488	138	9.27	NA			804	51	6.34	NA		
	National surveillance	<i>PCR or serology</i>	NA			NA	1,344	NA	NA			NA	997	NA	NA			NA	699	NA	NA			NA	265	NA
Norway	Trondheim	PCR	3,306	230	6.96	1,556	113	7.26	2,330	56	2.40	1,041	26	2.50	2,014	48	2.38	920	22	2.39	1,263	0	0.00	486	0	0.00
Southern Europe																										
Portugal	Coimbra ^a	PCR	803	5	0.62	374	4	1.07	924	90	9.74	460	38	8.26	1,084	19	1.75	469	8	1.71	161	0	0.00	69	0	0.00
Greece	Athens (A) ^a	<i>IgM ELISA</i>	212	19	8.96	92	9	9.78	236	51	21.61	125	32	25.60	250	65	26.00	118	28	23.73	167	35	20.96	73	15	20.55
		<i>IgG ELISA</i>	212	44	20.75	92	19	20.65	236	29	12.29	125	13	10.40	250	37	14.80	118	16	13.56	167	41	24.55	73	19	26.03
	Athens (B) ^a	<i>IgM ELISA</i>	185	9	4.86	90	3	3.33	181	15	8.29	87	6	6.90	231	27	11.69	106	14	13.21	172	14	8.14	90	8	8.89
		<i>IgG ELISA</i>	185	59	31.89	90	25	27.78	181	88	48.62	87	46	52.87	231	92	39.83	106	46	43.40	172	44	25.58	90	20	22.22
Slovenia	Ljubljana	PCR	530	19	3.58	708	7	0.99	745	119	15.97	857	75	8.75	1,326	402	30.32	1,382	218	15.77	320	14	4.38	528	8	1.52
Asia																										
Western Asia																										
Israel	Jerusalem	PCR	256	17	6.64	573	19	3.32	337	39	11.57	610	33	5.41	364	29	7.97	760	25	3.29	216	0	0.00	275	0	0.00
Eastern Asia																										
Japan	Kurashiki City (Okayama) ^a	PCR	30	4	13.33	16	2	12.50	64	14	21.88	26	5	19.23	34	3	8.82	15	1	6.67	5	0	0.00	5	0	0.00
	Tokyo	Rapid antigen test	25	NA	NA	52	33	63.46	80	25	31.25	60	9	15.00	420	22	5.24	180	14	7.78	60	3	5.00	60	1	1.67
Taiwan	Taoyuan ^a	PCR	116	20	17.24	56	11	19.64	159	63	39.62	77	31	40.26	204	131	64.22	113	71	62.83	44	5	11.36	16	0 ^b	0.00
South-eastern Asia																										
Singapore	Singapore ^a	PCR	4,212	387	9.19	NA			8,765	307	3.50	NA			15,860	613	3.87	NA			8,835	33	0.37	NA		
South Asia																										
India	New Delhi	<i>IgM ELISA</i>	159	12	7.55	30	7	23.33	207	7	3.38	105	8	7.62	113	14	12.39	67	7	10.45	84	13	15.48	49	5	10.20
America																										
Northern America																										
United States	Chicago ^a	PCR	3,818	10	0.26	1,892	3	0.16	3,873	21	0.54	1,814	15	0.83	4,653	39	0.84	2,258	21	0.93	1,589	2	0.13	735	0	0.00
Caribbean																										
Cuba	National surveillance	PCR	535	12	2.24	398	6	1.51	38	1	2.63	25	0	0.00	497	15	3.02	385	6	1.56	0	NA	NA	0	NA	NA
Oceania																										
Australia	Darlinghurst (Sydney)	PCR	3,975	35	0.88	8,303	36	0.43	3,050	30	0.98	6,241	22	0.35	4,784	111	2.32	11,242	82	0.73	9,487	10	0.11	36,408	10	0.03
New Zealand	Auckland	PCR	154	11	7.14	252	10	3.97	167	8	4.79	475	13	2.74	226	22	9.73	401	21	5.24	561	3	0.53	1,219	3	0.25

COVID-19: coronavirus disease; ELISA: enzyme-linked immunosorbent assay; Ig: immunoglobulin; NA: not available; UN: United Nations.

^a ≥90% of data are from children and adolescents <18 years of age.

^b Statistically significant difference in proportions of children/adolescents or females with positive tests between April 2020 and March 2021 and between April 2017 and March 2020 (Fisher's exact test, p < 0.05).

For serology only total test numbers of IgM considered. Entries in italics signify serological data (≠PCR).

Survey administration

Dissemination of the survey to invite participation was mixed-mode through societies (ESCMID, ESGMAC, International Organisation for Mycoplasma (IOM) and national societies for infectious diseases and microbiology via newsletter or email distribution lists), social media (ESCMID, ESGMAC, IOM and personal accounts of authors), and through in-person contact to potential participants by one of the authors (P.M.M.S). Potential participants were defined as authors of publications about *M. pneumoniae* epidemiology (PubMed search terms: “Mycoplasma pneumoniae” [title] and “epidemiology” [all fields], 1 January 2000 to 30 March 2021; search results: 439), and more than 300 corresponding authors were approached via email. The email was accompanied by a one-page study description on behalf of the ESGMAC, the survey in PDF and Word format and the link to the online survey. Close attention was paid to ensure that all UN regions were represented during dissemination of the survey. Participation was voluntary and without compensation. There was no mechanism in place to acknowledge receipt of the survey if a laboratory did not provide information. Consent to publish the data and be listed as a participant was declared on the first page of the questionnaire. The survey was launched on 30 March 2021. Reminders were sent out after 4 and 6 weeks via social media and email. The survey was closed on 31 May 2021.

Data collection

Quality control

Entries were included if they met the following quality control criteria for valid datasets: (i) verification of the participant, laboratory and institution via provided link and/or references in PubMed, (ii) validation of the information and/or references about the test method, and (iii) data check for multiple entries from the same institutions (double reporting), invalid or incomplete data, and inconsistent entries. In case of inconsistency or multiple entries from the same institutions, participants were contacted by email to request clarification and/or adapt entries to exclude double reporting. Criteria for de-duplication and exclusion criteria are listed in Supplementary Table S2.

Case definition

Because of local variation in the definition of *M. pneumoniae* infection, absence of clinical data and the difficulty to differentiate between *M. pneumoniae* infection and carriage [24], this study collated information on *M. pneumoniae* detections and not infections. A case was defined as *M. pneumoniae* detection in an individual with currently available test methods. Detailed information about microbiological detection methods (technique, product and company or reference) is listed in Table 1. A positive IgM, IgG or IgA serology was defined as antibody level above the cut-off of the test, as indicated by the manufacturer (Table 1). Participants were asked

whether a positive serology was confirmed by a four-fold increase in IgG levels measured in convalescent samples (as serological gold standard for *M. pneumoniae* infection [11]).

Stay-at-home order and school closure periods

Periods of stay-at-home orders for the general population (referred to as lockdowns) in Europe were obtained from the Response Measures Database (RMD) of the European Centre for Disease Prevention and Control (ECDC) [25] and those in other UN regions from a collection of pandemic lockdown dates in Wikipedia [26], with adjustments made by the participants. The total duration in days until the end of the study period was calculated for each site. School closure duration in days (full and partial closure in total) was determined according to the United Nations Children’s Fund (UNICEF) global school closures database until 2 March 2021 (last update before the end of the study period) [27].

Statistical analysis

Incidence was defined as the number of new cases over a specified period of time within a community [28]. Given the missing population denominators we were not able to report incidence rates. We compared *M. pneumoniae* detections between April 2020 and March 2021 with total numbers observed from April 2017 to March 2020. Fisher’s exact test was used to compare proportions with corrections for multiple testing. Spearman rank correlation coefficient (R , ρ) was used for analyses of correlation. All reported p values are two-tailed with statistical significance defined as $p < 0.05$. Data were analysed using R software (version 4.0.5) [29].


Results

Survey entries and detection methods

We received entries from 48 sites, of which 29 were entered via the online survey and 19 via email to authors. Of the 12 experts collating laboratory detections of *M. pneumoniae* in Europe and Israel for the ESGMAC in a previous study (January 2011–April 2016) [14], eight provided information for this survey. An overall response rate could not be calculated because the survey was widely disseminated through societies, social media and further dissemination among participants themselves. We excluded 11 entries because of invalid or incomplete data ($n=7$), inconsistent data ($n=2$; positive test numbers by month did not match with total numbers per year) or double reporting ($n=2$; congruent data from same institutions). Thus, 37 valid datasets from separate sites in 21 countries from four UN regions were eligible for inclusion (Europe: $n=12$; Asia: $n=5$; America: $n=2$; Oceania: $n=2$), 29 from hospital laboratories, two from national reference laboratories and six from national and/or regional surveillance systems (Figure 1).

FIGURE 3

Detection of *Mycoplasma pneumoniae* at sites that provided single-sample serological data in addition to PCR, April 2017–March 2021 (n = 14,702^a)



^a For serology only total test numbers of IgM considered.

Grey backgrounds indicate local stay-at-home order (lockdown) periods. Another site from Germany (Homburg) did also provide PCR and serological data separately but numbers by month were not available.

Demographic characteristics and laboratory information of participating sites are shown in Table 1. The detection method varied between sites: 29 (78.38%) sites reported exclusively PCR (n=17 multiplex); three sites used exclusively serology (enzyme-linked immunosorbent assay (ELISA)), three sites reported combined PCR and serology (no distinction possible between detection methods, but predominantly serology), one site used a combination of direct test methods (i.e. PCR, antigen test or culture) and one site used exclusively rapid antigen testing. Three sites reported only the number of positive tests over the entire study period (Saxony (Germany) and national surveillance systems of Belgium and Finland), and another three sites provided serological data in addition to PCR.

Detections before and after the introduction of non-pharmaceutical interventions

A total of 631,104 tests were performed during the study period from April 2017–March 2021 (three sites did not have data about total test numbers available). Overall, 30,617 *M. pneumoniae* detections were confirmed from participating sites. Among those with available information on age/sex, 54.92% (n=11,029/20,081) were reported in children/adolescents younger than 18 years of age and 52.90% (n=12,794/24,184) in females. The greatest number of positive tests were obtained with direct test methods (n=19,102; 62.39%; predominantly PCR) followed by a combination of PCR and serology (n=10,483; 34.24%; no information on isotypes) or

serology alone (n=1,032; 3.37%; only IgM was considered if all isotypes were reported). Information about convalescent samples for serological testing was not available. No routine testing for a fourfold increase in IgG levels was reported. De-duplication data were determined at site level (Supplementary Table S2 lists the reporting characteristics per site).

There was a significant reduction of *M. pneumoniae* detections after the introduction of NPIs (Figure 2). Among total detections, 1,714 (5.60%) derived from April 2020 to March 2021 compared with 28,903 (94.40%) from April 2017 to March 2020 (Table 2). *Mycoplasma pneumoniae* testing and detection in children/adolescents and females per year is shown in Table 3. The annual proportion of children/adolescents and females with detections before and during the COVID-19 pandemic was 55.16% vs 49.77% (p<0.01) and 53.01% vs 50.86% (p=0.15), respectively. Detailed graphs for each site and country are shown in Supplementary Figures S1–S6. The difference in detections before and during the COVID-19 pandemic was more obvious for direct test methods (Figure 2A) than indirect test methods (Figure 2B). This is supported by a direct comparison of detections with PCR and single-sample serology (IgM, IgG and IgA) from the three sites that reported data separately for each method, which did not show any correlation between those two test methods (Figure 3).

TABLE 4

Macrolide-resistant *Mycoplasma pneumoniae* testing and detection rates per year, April 2017–March 2021 (n = 784)

UN region and country	City or region	Macrolide resistance determination (reference)	April 2017–March 2018			April 2018–March 2019			April 2019–March 2020			April 2020–March 2021 (COVID-19 pandemic)			Difference in detection rate (%)		p ^b
			Total tests (N)	Positive tests (n)	Detection rate (%)	Total tests (N)	Positive tests (n)	Detection rate (%)	Total tests (N)	Positive tests (n)	Detection rate (%)	Total tests (N)	Positive tests (n)	Detection rate (%)	pre-pandemic vs COVID-19 pandemic ^a		
Europe																	
Western Europe																	
France	Bordeaux	[48]	10	0	0.00	15	2	13.33	30	3	10.00	3	0	0.00	-100.00	1.00	
Switzerland	Zurich (A+B) ^d	[50]	0	NA	NA	2	2	100.00	10	7	70.00	3	1	33.33	-55.56	0.24	
Belgium	Antwerp, Leuven (national reference laboratory)	[48]	26	1	3.85	15	0	0.00	30	0	0.00	2	0	0.00	-100.00	1.00	
England	National reference laboratory ^e	[55]	19	3	15.79	11	0	0.00	104	1	0.96	6	0	0.00	-100.00	1.00	
Asia																	
Eastern Asia																	
Japan	National surveillance	[58]	103	20	19.42	97	5	5.15	124	18	14.52	8	0	0.00	-100.00	0.60	
Taiwan	Taoyuan ^c	[59]	10	6	60.00	53	42	79.25	80	62	77.50	0	NA	NA	NA	NA	
America																	
Caribbean																	
Cuba	National surveillance	[60]	14	2	14.29	0	NA	NA	9	2	22.22	0	NA	NA	NA	NA	

COVID-19: coronavirus disease; SD: standard deviation; MRMP: macrolide-resistant *Mycoplasma pneumoniae*; NA: not applicable; UN: United Nations.

^a Difference in detection rate between April 2017 and March 2020 (mean positive/total tests across the 3 years) and April 2020 and March 2021 (absolute number positive/total tests). Percentages showing a reduction in detection rate are indicated in bold.

^b Proportions of positive/total tests from April 2020 to March 2021 were compared with total numbers from April 2017 to March 2020 by Fisher's exact test.

^c ≥90% of data are from children and adolescents <18 years of age.

^d Macrolide resistance determination only upon physician's request in case of clinically suspected MRMP infection. Data reported for both sites from Zurich (A+B).

^e Period of enhanced surveillance from 1 October 2019 to 30 March 2020.

Entries in italics signify macrolide resistance determination only upon physician's request in case of clinically suspected MRMP infection.

Following the introduction of NPIs, the *M. pneumoniae* incidence by direct test methods decreased significantly from 8.61%±10.62 (mean of incidences from each site±standard deviation) during April 2017 to March 2020 to 1.69%±3.30 in April 2020 to March 2021 ($p<0.01$). The detection rates decreased with direct but not with indirect test methods (−93.51% vs +18.08%; $p<0.01$) (Table 2). Although 27 sites reported also a reduction in total number of tests (−44.52%±24.61) in April 2020 to March 2021, seven sites showed an increase in total test numbers during the COVID-19 pandemic (because SARS-CoV-2 PCR was included in a multiplex panel that also contained *M. pneumoniae* PCR) (Table 2). In the year before the introduction of NPIs (April 2019 to March 2020), direct *M. pneumoniae* detections were significantly increased in several countries across UN regions compared with the period April 2018 to March 2019, which was indicative of an *M. pneumoniae* epidemic (Figure 2A).

Total duration of lockdown (82.80 days±55.73; range: 0–240) and school closure periods (84.05 days±56.33; range: 0–235) varied widely across countries. There was no correlation of the duration of lockdown or school closure periods with direct *M. pneumoniae* detection rates from April 2020 to March 2021. Several sites reported a longer duration of lockdown than school closure periods, which suggested that children returned to schools while lockdown continued for some time (Table 1). The re-opening of schools had no observable impact on the incidence of *M. pneumoniae* as direct detections remained remarkably low throughout the period April 2020 to March 2021. Detections were very low or absent even in countries where no school closures or official lockdowns were enforced (e.g. Japan, Taiwan; see Supplementary Figure S3 for *M. pneumoniae* detections in Asia).

Macrolide resistance

As a consequence of the significant decrease in *M. pneumoniae* detections after the introduction of NPIs, only few cases were investigated for macrolide resistance. In total, seven sites from Europe, Asia and America reported MRMP rates from April 2017 to March 2021 (Table 4). Macrolide resistance determination was reported as part of national surveillance of positive samples (Japan, Cuba) or only on positive samples identified at the reference laboratory and/or upon physician request. The MRMP detections among investigated cases are shown as absolute numbers in Figure 4A and as percentages in Figure 4B. The highest MRMP rate was found in Taiwan from April 2018 to March 2019 with 42 of 53 isolates. The national surveillance from Japan contributed the greatest number of strains investigated for macrolide resistance. Overall, MRMP was detected in one of 22 investigated cases from April 2020 to March 2021 and in 176 of 762 (23.10%) from April 2017 to March 2020 ($p=0.04$).

Discussion

This global survey showed that all countries experienced a decrease in *M. pneumoniae* incidence by direct test methods in April 2020–March 2021, relative to the previous three years. This decline corresponded with the timing of the implementation of NPIs against COVID-19 in March 2020 in each country. We also observed a decrease in MRMP rates in April 2020 to March 2021. The MRMP rates before the COVID-19 pandemic were lower in Europe than in America or Asia, consistent with previous reports [11].


A reduction in *M. pneumoniae* detections after the introduction of NPIs was observed with direct test methods such as PCR but not with serology. This effect could be explained by the long-lasting nature of antibodies against *M. pneumoniae*. *Mycoplasma pneumoniae*-specific antibodies (IgM and IgG) persist for months to years after infection, and significantly longer than *M. pneumoniae* DNA in the upper respiratory tract [30,31]. Based on these kinetics, we would expect a decline in positive IgM serology in the second year of the COVID-19 pandemic, but not necessarily in IgG serology as *M. pneumoniae*-specific IgG antibodies can persist lifelong [30]. There is also the possibility of false-positive results caused by limited assay performance [32] as serological detections are reported from single-sample serology, which was in most cases not confirmed by the detection of a significant antibody level change in convalescent sera. In addition, PCR and serology (IgM and IgG) can be positive in asymptomatic carriers [11]. The detection of specific antibody-secreting cells by enzyme-linked immunospot (ELISpot) assay may allow for differentiation between infection and carriage [24], and a combination of clinical features and biomarkers can help identify patients at high risk for *M. pneumoniae* community-acquired pneumonia [15]. However, no clinical features were reported in this study and cases were defined by local practice.

Our findings are in line with several reports about a worldwide reduction in infections with respiratory and gastrointestinal pathogens after the introduction of NPIs [2,3,5,7,33–37]. The incidence of invasive bacterial diseases caused by *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria meningitidis* that are transmitted via the respiratory route were also considerably reduced during the early months of the COVID-19 pandemic [38]. The interruption of direct person-to-person transmission was suspected to be the most plausible explanation for the reduction in respiratory infections. These remained low even after the re-opening of schools, except for rhinovirus [6,39–41].

Direct detections of *M. pneumoniae* between April 2020 and March 2021 were significantly below levels of non-epidemic periods of *M. pneumoniae* across countries despite widely differing lockdown or school closure periods, and even in countries where no official lockdowns or school closures were enforced.

FIGURE 4

Macrolide-resistant *Mycoplasma pneumoniae* testing and detection in different countries across the world, April 2017–March 2021 (n = 784)



MRMp: Macrolide-resistant *Mycoplasma pneumoniae*.

The coloured parts of the bar graph with numbers represent absolute numbers or proportions of MRMp detection (the colours correspond with colours for sites in Figure 2). Data derived from the COVID-19 pandemic (April 2020–March 2021) are indicated by a grey background. Japan and Cuba reported national MRMp surveillance data (Table 4). Macrolide resistance determination in Switzerland was performed only upon request from a physician (in case of clinically suspected MRMp infection).

This suggests that the observed low *M. pneumoniae* incidence may be explained by the continuation of NPIs such as personal protective and physical distancing measures. Other factors that may be involved in restricting *M. pneumoniae* transmission are behavioural responses to the pandemic (e.g. limited mobility related to COVID-19) and change in health-care utilisation (e.g. telemedicine visits). After the re-opening of schools, direct *M. pneumoniae* detections remained low. This was also observed at sites where lockdown and restrictions for the adult population continued while children returned to schools. Children have greater difficulty adhering to physical distancing and personal protective measures so that *M. pneumoniae* transmission may be less effectively prevented in schools than in the adult population. Unfortunately, we did not have information on the age distribution in children to look at the pre-school and school age groups separately. The low incidence despite the re-opening of schools might suggest that adults play a more important role in transmission of *M. pneumoniae* than previously thought. This is supported by the observed decrease in the proportion of children and adolescents with *M. pneumoniae* detection during the COVID-19 pandemic. Notably, there was no change in the proportion of females with *M. pneumoniae* infection before and during the COVID-19 pandemic. Reduced transmission by shielding of adults (regardless of school closures) was also discussed as possible reason for the decrease in invasive pneumococcal disease [38]. Interestingly, nasopharyngeal pneumococcal carriage in children was only slightly reduced during the first year of the COVID-19 pandemic and the reduction in invasive pneumococcal disease was therefore attributed to the suppression of specific respiratory viruses such as RSV and influenza, which are often implicated as co-pathogens with *S. pneumoniae* [42]. *Mycoplasma pneumoniae* is also frequently detected with other viruses in the upper respiratory tract [15,43-45], but the role of co-detections in *M. pneumoniae* respiratory disease remains unclear [44]. A direct biological effect of SARS-CoV-2 on *M. pneumoniae* by interference or interaction could be another explanation. To our knowledge, data supporting this hypothesis do not exist so far. Further, transient herd immunity from the recent epidemic period in April 2019–March 2020 in several countries in Europe and Asia could have led to a decreased *M. pneumoniae* incidence during the COVID-19 pandemic [12]. However, the incidence was also reduced in countries that had not experienced a recent epidemic (e.g. Norway).

The study has a number of limitations. Firstly, because of the variable reporting methods and testing criteria at each site, conclusions based on the analysis across countries must be considered with caution. Data obtained from a single hospital laboratory from a specific region may not be fully representative of the country as a whole. No information about catchment area and numbers of laboratories within regions were available. The study also lacks representation from Africa

and South America (no survey response and/or no testing for *M. pneumoniae* reported). Secondly, defining study-wide case definitions and de-duplication criteria was not feasible given the heterogeneous nature of data collection between sites. De-duplication methodologies were therefore set at site level. Thirdly, as mentioned previously, serological detections were not confirmed by antibody changes in paired sera in most cases. Fourthly, analysis of the local clinical testing pathway for *M. pneumoniae* was not possible within this study. Decision-making to test or not to test with specific methodologies during the COVID-19 pandemic may have impacted which individuals and sites offered testing at which time. The number of tests increased in one fifth of the sites during the period April 2020 to March 2021 and also the incidence was significantly lower compared with the pre-pandemic period; hence, we do not believe that the overall reduction in *M. pneumoniae* detections can solely be accounted for by reduced testing. Nor was there an indication that *M. pneumoniae* testing was reduced because of shifting laboratory resources towards SARS-CoV-2 testing during the whole first year after the introduction of NPIs covered by this study. Finally, an overall survey response rate could not be calculated because of the widespread dissemination of the survey. Incomplete response to a survey can introduce a bias related to differences in incidence between the responders and the non-responders [21,46]. However, this risk seems minimal as our survey dealt with microbiological laboratory data and generated a large and varied sample [46].

This study is another example of how pandemic-focused public health measures may have prevented infections caused by other respiratory pathogens. The COVID-19 pandemic resulted in restrictive NPIs such as lockdowns and school closures, which are unsustainable in the longer term. The results of this study suggest that even less restrictive NPIs such as personal protective and physical distancing measures might have prevented transmission of *M. pneumoniae* in the community.

The study also highlights the importance of establishing international working groups to investigate pathogen epidemiology where surveillance systems are lacking. It underlines the need for an international case definition for infection with *M. pneumoniae* (detection method and clinical criteria). The influence of the detection method for epidemiological surveillance of *M. pneumoniae* is shown in the discrepancy between PCR and single-sample serology in this study. Serological surveillance of *M. pneumoniae* may be only accurate by using paired sera in order to detect a fourfold increase in IgG levels [11]. However, such procedures are time-consuming and are not useful for acute patient care. A more rapid response to public health measures may be obtained by surveillance of *M. pneumoniae* using PCR. Finally, epidemiological surveillance should also include antimicrobial resistance testing of *M.*

pneumoniae. This study represents the most comprehensive estimate of global resistance documented to date and is important for clinicians and infectious disease surveillance considering that macrolides remain the main global treatment option for children with *M. pneumoniae* infection.

Conclusion

The results of this study from diverse geographical locations and healthcare settings suggest that the implementation of NPIs against COVID-19 probably restricted transmission of *M. pneumoniae*, leading to a significant reduction in *M. pneumoniae* infections in many countries across the world from April 2020 to March 2021. The retention of some NPIs after the COVID-19 pandemic e.g. improved hand hygiene, respiratory etiquette or physical distancing in the community, or the use of masks in health care institutions may help reduce the burden of *M. pneumoniae* infections. The large collaborative network established for this study allows to assess the resurgence of *M. pneumoniae* infections at a later time.

ESGMAC–MyCOVID Study Team

Noémie Wagner, Corinne Andreutti, Philipp K. A. Agyeman, Christoph Aebi, Michael Buettcher, Lisa Kottanattu, Valeria Gaia, Frank Imkamp, Reinhard Zbinden, Christoph Berger, Anita Niederer-Loher, Florence Barbey, Adrian Egli, Hanna Schmid, Ulrich Heininger, Cihan Papan, Malte Kohns Vasconcelos, Birgit Henrich, Colin Mackenzie, Gerlinde Schneider, Mireille van Westreenen, Nelianne J. Verkaik, Annemarie M.C. van Rossum, Hanne-Dorthe Emborg, Ville Peltola, Marjo Renko, Terhi Tapiainen, Santtu Heinonen, Henrik Døllner, Fernanda Rodrigues, Minos Matsas, Eleni Kalogera, Evangelia Petridou, Ioannis Kopsidas, Theoklis E. Zaoutis, Ayelet Michael-Gayego, Kazunobu Ouchi, Ho Namkoong, Yu-Chia Hsieh, Matthias Maiwald, Liat Hui Loo, Rama Chaudhry, Larry K. Kociolek, Nadia Rodríguez, David Lorenz, Mary De Almeida

Funding statement

PMMS was supported by a Walter und Gertrud Siegenthaler Fellowship and the career development program “Filling the Gap” of the University of Zurich, outside of this study. The ESGMAC covered costs for the survey development and administration.

Ethical statement

This study collected aggregated and anonymized data. The need for ethics approval for this study varied by country, and was administered by participants if required (Supplementary Table S2).

Acknowledgements

We are very grateful to all those who helped with the study: Laure F. Pittet (Department of Pediatrics, Division of General Pediatrics, Children’s Hospital, Faculty of Medicine, University of Geneva Hospitals, Geneva, Switzerland); Petra

Zimmermann (Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland); Jan Fehr (Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland); Lucas M. Bachmann (Medignition Inc. Research Consultants, Zurich, Switzerland); Semjon Sidorov (Division of Infectious Diseases and Hospital Epidemiology, University Children’s Hospital Zurich, Zurich, Switzerland); Wendy W.J. Unger (Division of Infectious Diseases and Immunology, Department of Pediatrics, Erasmus MC University Medical Center–Sophia Children’s Hospital, Rotterdam, The Netherlands); Samuel Rhedin (Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden); Todd A. Florin (Feinberg School of Medicine, Northwestern University, Chicago, IL, USA); Lilliam Ambroggio (Sections of Emergency Medicine and Hospital Medicine, Department of Pediatrics, Children’s Hospital Colorado, University of Colorado, Denver, CO, USA); Asha C. Bowen (Department of Infectious Diseases, Perth Children’s Hospital, Perth, Western Australia, Australia); ESCMID: William Caddy (executive office), Patrick Kudyba (science coordinator); Swiss Society for Infectious Diseases (SSI): Pierre-Yves Bochud (president); Pediatric Infectious Disease Group of Switzerland (PIGS): Andrea Duppenhaler (secretary); Swiss Society for Microbiology (SSM): Nathalie Mermoud (general secretary).

Conflict of interest

None declared.

Authors’ contributions

Study conceptualisation and lead: PMMS. Study design: PMMS, MLB, RNP, RD. Acquisition of data: all authors including all ESGMAC–MyCOVID Study Team members. Analysis and interpretation of data: PMMS, MLB, SAU, NB, MV, KL, SP, CB, DK, JD, BA, VJC, GG, RNP, RD. Writing of the original manuscript draft: PMMS. Formal analysis: PMMS, MLB, RNP, RD. All authors, including all ESGMAC–MyCOVID Study Team members, contributed to the work, reviewed and approved the manuscript.

References

1. Cowling BJ, Ali ST, Ng TWY, Tsang TK, Li JCM, Fong MW, et al. Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. *Lancet Public Health*. 2020;5(5):e279-88. [https://doi.org/10.1016/S2468-2667\(20\)30090-6](https://doi.org/10.1016/S2468-2667(20)30090-6) PMID: 32311320
2. Oster Y, Michael-Gayego A, Rivkin M, Levinson L, Wolf DG, Nir-Paz R. Decreased prevalence rate of respiratory pathogens in hospitalized patients during the COVID-19 pandemic: possible role for public health containment measures? *Clin Microbiol Infect*. 2021;27(5):811-2. <https://doi.org/10.1016/j.cmi.2020.12.007> PMID: 33352303
3. Huang QS, Wood T, Jelley L, Jennings T, Jefferies S, Daniells K, et al. ; Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand. *Nat Commun*. 2021;12(1):1001. <https://doi.org/10.1038/s41467-021-21157-9> PMID: 33579926
4. Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. *Proc Natl Acad Sci USA*. 2020;117(48):30547-53. <https://doi.org/10.1073/pnas.2013182117> PMID: 33168723
5. Emborg HD, Carnahan A, Bragstad K, Trebbien R, Brytting M, Hungnes O, et al. Abrupt termination of the 2019/20 influenza season following preventive measures against

- COVID-19 in Denmark, Norway and Sweden. *Euro Surveill.* 2021;26(22):2001160. <https://doi.org/10.2807/1560-7917.ES.2021.26.22.2001160> PMID: 34085632
6. Haapanen M, Renko M, Artama M, Kuitunen I. The impact of the lockdown and the re-opening of schools and day cares on the epidemiology of SARS-CoV-2 and other respiratory infections in children - A nationwide register study in Finland. *EclinicalMedicine.* 2021;34:100807. <https://doi.org/10.1016/j.eclinm.2021.100807> PMID: 33817612
 7. Wan WY, Thoon KC, Loo LH, Chan KS, Oon LLE, Ramasamy A, et al. Trends in respiratory virus infections during the COVID-19 pandemic in Singapore, 2020. *JAMA Netw Open.* 2021;4(6):e2115973. <https://doi.org/10.1001/jamanetworkopen.2021.15973> PMID: 34181015
 8. von Hammerstein AL, Aebi C, Barbey F, Berger C, Buettcher M, Casaulta C, et al. Interseasonal RSV infections in Switzerland - rapid establishment of a clinician-led national reporting system (RSV EpiCH). *Swiss Med Wkly.* 2021;151(35-36):w30057. <https://doi.org/10.4414/SMW.2021.w30057> PMID: 34499459
 9. Zhang Y, Quigley A, Wang Q, MacIntyre CR. Non-pharmaceutical interventions during the roll out of covid-19 vaccines. *BMJ.* 2021;375(2314):n2314. <https://doi.org/10.1136/bmj.n2314> PMID: 34853011
 10. Zhang Y, Huang Y, Ai T, Luo J, Liu H. Effect of COVID-19 on childhood Mycoplasma pneumoniae infection in Chengdu, China. *BMC Pediatr.* 2021;21(1):202. <https://doi.org/10.1186/s12887-021-02679-z> PMID: 33910509
 11. Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. Mycoplasma pneumoniae from the respiratory tract and beyond. *Clin Microbiol Rev.* 2017;30(3):747-809. <https://doi.org/10.1128/CMR.00114-16> PMID: 28539503
 12. Jacobs E, Ehrhardt I, Dumke R. New insights in the outbreak pattern of Mycoplasma pneumoniae. *Int J Med Microbiol.* 2015;305(7):705-8. <https://doi.org/10.1016/j.ijmm.2015.08.021> PMID: 26319941
 13. Uldum SA, Bangsbo JM, Gahrn-Hansen B, Ljung R, Mølvadgaard M, Føns Petersen R, et al. Epidemic of Mycoplasma pneumoniae infection in Denmark, 2010 and 2011. *Euro Surveill.* 2012;17(5):20073. <https://doi.org/10.2807/ese.17.05.20073-en> PMID: 22321137
 14. Beeton ML, Zhang XS, Uldum SA, Bébéar C, Dumke R, Gullsby K, et al. Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016. *Euro Surveill.* 2020;25(2):1900112. <https://doi.org/10.2807/1560-7917.ES.2020.25.2.1900112> PMID: 31964459
 15. Meyer Sauter PM, Krautter S, Ambroggio L, Seiler M, Paioni P, Relly C, et al. Improved diagnostics help to identify clinical features and biomarkers that predict Mycoplasma pneumoniae community-acquired pneumonia in children. *Clin Infect Dis.* 2020;71(7):1645-54. <https://doi.org/10.1093/cid/ciz1059> PMID: 31665253
 16. Dorigo-Zetsma JW, Wilbrink B, van der Nat H, Bartelds AI, Heijnen ML, Dankert J. Results of molecular detection of Mycoplasma pneumoniae among patients with acute respiratory infection and in their household contacts reveals children as human reservoirs. *J Infect Dis.* 2001;183(4):675-8. <https://doi.org/10.1086/318529> PMID: 11170998
 17. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. *Clin Microbiol Rev.* 2004;17(4):697-728. <https://doi.org/10.1128/CMR.17.4.697-728.2004> PMID: 15489344
 18. Loens K, Ieven M. Mycoplasma pneumoniae: current knowledge on nucleic acid amplification techniques and serological diagnostics. *Front Microbiol.* 2016;7:448. <https://doi.org/10.3389/fmicb.2016.00448> PMID: 27064893
 19. Meyer Sauter PM, Unger WWJ, Nadal D, Berger C, Vink C, van Rossum AMC. Infection with and carriage of Mycoplasma pneumoniae in children. *Front Microbiol.* 2016;7:329. <https://doi.org/10.3389/fmicb.2016.00329> PMID: 27047456
 20. Dumke R, Benitez AJ, Chalker V, Gullsby K, Henrich B, Hidalgo-Grass C, et al. Multi-center evaluation of one commercial and 12 in-house real-time PCR assays for detection of Mycoplasma pneumoniae. *Diagn Microbiol Infect Dis.* 2017;88(2):111-4. <https://doi.org/10.1016/j.diagmicrobio.2017.03.004> PMID: 28318608
 21. Pulcini C, Leibovici L, CMI Editorial Office. CMI guidance for authors of surveys. *Clin Microbiol Infect.* 2016;22(11):901-2. <https://doi.org/10.1016/j.cmi.2016.08.015> PMID: 27599691
 22. Bennett C, Khangura S, Brehaut JC, Graham ID, Moher D, Potter BK, et al. Reporting guidelines for survey research: an analysis of published guidance and reporting practices. *PLoS Med.* 2010;8(8):e1001069. <https://doi.org/10.1371/journal.pmed.1001069> PMID: 21829330
 23. SurveyMonkey. How SurveyMonkey gets its data. [Accessed: 30 April 2021]. Available from: www.surveymonkey.com/mp/survey-methodology
 24. Meyer Sauter PM, Seiler M, Trück J, Unger WWJ, Paioni P, Relly C, et al. Diagnosis of Mycoplasma pneumoniae pneumonia with measurement of specific antibody-secreting cells. *Am J Respir Crit Care Med.* 2019;200(8):1066-9. <https://doi.org/10.1164/rccm.201904-0860LE> PMID: 31251669
 25. European Centre for Disease Prevention and Control (ECDC). Data on country response measures to COVID-19. Stockholm: ECDC. [Accessed: 30 April 2021]. Available from: <https://www.ecdc.europa.eu/en/publications-data/download-data-response-measures-covid-19>
 26. Wikipedia. COVID-19 lockdowns. [Accessed: 30 April 2021]. Available from: https://en.wikipedia.org/wiki/COVID-19_lockdowns
 27. United Nations Children's Fund (UNICEF). COVID-19 and school closures. New York: UNICEF; 2021. Available from: <https://data.unicef.org/resources/one-year-of-covid-19-and-school-closures>
 28. Center for Disease Control and Prevention (CDC). Principles of epidemiology in public health practice. 3rd Edition. Lesson 3: Measures of risk. Atlanta: CDC; 2012 Available from: <https://www.cdc.gov/csels/dsepd/ss1978/lesson3/section2.html>
 29. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2021. Available from: <http://www.R-project.org>
 30. Meyer Sauter PM, Trück J, van Rossum AMC, Berger C. Circulating antibody-secreting cell response during Mycoplasma pneumoniae childhood pneumonia. *J Infect Dis.* 2020;222(1):136-47. <https://doi.org/10.1093/infdis/jiaa062> PMID: 32034406
 31. Nir-Paz R, Michael-Gayego A, Ron M, Block C. Evaluation of eight commercial tests for Mycoplasma pneumoniae antibodies in the absence of acute infection. *Clin Microbiol Infect.* 2006;12(7):685-8. <https://doi.org/10.1111/j.1469-0691.2006.01469.x> PMID: 16774570
 32. Beersma MF, Dirven K, van Dam AP, Templeton KE, Claas EC, Goossens H. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard". *J Clin Microbiol.* 2005;43(5):2277-85. <https://doi.org/10.1128/JCM.43.5.2277-2285.2005> PMID: 15872256
 33. Angoulvant F, Ouldali N, Yang DD, Filser M, Gajdos V, Rybak A, et al. Coronavirus disease 2019 pandemic: impact caused by school closure and national lockdown on pediatric visits and admissions for viral and nonviral infections - a time series analysis. *Clin Infect Dis.* 2021;72(2):319-22. <https://doi.org/10.1093/cid/ciaa710> PMID: 33501967
 34. Rhedin SA, Ryd Rinder M, Hildenwall H, Herlenius E, Hertting O, Luthander J, et al. Reduction in paediatric emergency visits during the COVID-19 pandemic in a region with open preschools and schools. *Acta Paediatr.* 2021;110(10):2802-4. <https://doi.org/10.1111/apa.15978> PMID: 34107120
 35. Yeoh DK, Foley DA, Minney-Smith CA, Martin AC, Mace AO, Sikazwe CT, et al. Impact of coronavirus disease 2019 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian winter. *Clin Infect Dis.* 2021;72(12):2199-202. <https://doi.org/10.1093/cid/ciaa1475> PMID: 32986804
 36. Leuzinger K, Roloff T, Gosert R, Sogaard K, Naegle K, Rentsch K, et al. Epidemiology of severe acute respiratory syndrome coronavirus 2 emergence amidst community-acquired respiratory viruses. *J Infect Dis.* 2020;222(8):1270-9. <https://doi.org/10.1093/infdis/jiaa464> PMID: 32726441
 37. Ullrich A, Schranz M, Rexroth U, Hamouda O, Schaade L, Diercke M, et al. Impact of the COVID-19 pandemic and associated non-pharmaceutical interventions on other notifiable infectious diseases in Germany: An analysis of national surveillance data during week 1-2016 - week 32-2020. *Lancet Reg Health Eur.* 2021;6:100103. <https://doi.org/10.1016/j.lanepe.2021.100103> PMID: 34557831
 38. Brueggemann AB, Jansen van Rensburg MJ, Shaw D, McCarthy ND, Jolley KA, Maiden MCJ, et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. *Lancet Digit Health.* 2021;3(6):e360-70. [https://doi.org/10.1016/S2589-7500\(21\)00077-7](https://doi.org/10.1016/S2589-7500(21)00077-7) PMID: 34045002
 39. Kohns Vasconcelos M, Meyer Sauter PM, Keitel K, Santoro R, Heininger U, van den Anker J, et al. Strikingly decreased community-acquired pneumonia admissions in children despite open schools and day-care facilities in Switzerland. *Pediatr Infect Dis J.* 2021;40(4):e171-2. <https://doi.org/10.1097/INF.0000000000003026> PMID: 33399433
 40. Poole S, Brendish NJ, Tanner AR, Clark TW. Physical distancing in schools for SARS-CoV-2 and the resurgence of rhinovirus.

- Lancet Respir Med. 2020;8(12):e92-3. [https://doi.org/10.1016/S2213-2600\(20\)30502-6](https://doi.org/10.1016/S2213-2600(20)30502-6) PMID: 33289636
41. Oh DY, Buda S, Biere B, Reiche J, Schlosser F, Duwe S, et al. Trends in respiratory virus circulation following COVID-19-targeted nonpharmaceutical interventions in Germany, January - September 2020: Analysis of national surveillance data. *Lancet Reg Health Eur.* 2021;6:100112. <https://doi.org/10.1016/j.lanepe.2021.100112> PMID: 34124707
 42. Danino D, Ben-Shimol S, Van Der Beek BA, Givon-Lavi N, Avni YS, Greenberg D, et al. Decline in pneumococcal disease in young children during the COVID-19 pandemic in Israel associated with suppression of seasonal respiratory viruses, despite persistent pneumococcal carriage: A prospective cohort study. *Clin Infect Dis.* 2021;ciab1014. <https://doi.org/10.1093/cid/ciab1014> PMID: 34904635
 43. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. *N Engl J Med.* 2015;372(9):835-45. <https://doi.org/10.1056/NEJMoa1405870> PMID: 25714161
 44. Diaz MH, Cross KE, Benitez AJ, Hicks LA, Kutty P, Bramley AM, et al. Identification of bacterial and viral codetections with *Mycoplasma pneumoniae* using the TaqMan Array Card in patients hospitalized with community-acquired pneumonia. *Open Forum Infect Dis.* 2016;3(2):ofw071. <https://doi.org/10.1093/ofid/ofw071> PMID: 27191004
 45. Zheng X, Lee S, Selvarangan R, Qin X, Tang YW, Stiles J, et al. Macrolide-resistant *Mycoplasma pneumoniae*, United States. *Emerg Infect Dis.* 2015;21(8):1470-2. <https://doi.org/10.3201/eid2108.150273> PMID: 26196107
 46. Bates SM, Rogstad KE. Postal research: too many problems? *Sex Transm Infect.* 2000;76(5):332-4. <https://doi.org/10.1136/sti.76.5.332> PMID: 11141846
 47. Touati A, Benard A, Hassen AB, Bébéar CM, Pereyre S. Evaluation of five commercial real-time PCR assays for detection of *Mycoplasma pneumoniae* in respiratory tract specimens. *J Clin Microbiol.* 2009;47(7):2269-71. <https://doi.org/10.1128/JCM.00326-09> PMID: 19403761
 48. Peuchant O, Ménard A, Renaudin H, Morozumi M, Ubukata K, Bébéar CM, et al. Increased macrolide resistance of *Mycoplasma pneumoniae* in France directly detected in clinical specimens by real-time PCR and melting curve analysis. *J Antimicrob Chemother.* 2009;64(1):52-8. <https://doi.org/10.1093/jac/dkp160> PMID: 19429926
 49. Meyer Sauteur PM, Bleisch B, Voit A, Maurer FP, Relly C, Berger C, et al. Survey of macrolide-resistant *Mycoplasma pneumoniae* in children with community-acquired pneumonia in Switzerland. *Swiss Med Wkly.* 2014;144:w14041. PMID: 25254315
 50. Wagner K, Imkamp F, Pires VP, Keller PM. Evaluation of Lightmix *Mycoplasma* macrolide assay for detection of macrolide-resistant *Mycoplasma pneumoniae* in pneumonia patients. *Clin Microbiol Infect.* 2019;25(3):383.e5-7. <https://doi.org/10.1016/j.cmi.2018.10.006> PMID: 30391582
 51. Hardegger D, Nadal D, Bossart W, Altwegg M, Dutly F. Rapid detection of *Mycoplasma pneumoniae* in clinical samples by real-time PCR. *J Microbiol Methods.* 2000;41(1):45-51. [https://doi.org/10.1016/S0167-7012\(00\)00135-4](https://doi.org/10.1016/S0167-7012(00)00135-4) PMID: 10856776
 52. Ursi D, Dirven K, Loens K, Ieven M, Goossens H. Detection of *Mycoplasma pneumoniae* in respiratory samples by real-time PCR using an inhibition control. *J Microbiol Methods.* 2003;55(1):149-53. [https://doi.org/10.1016/S0167-7012\(03\)00131-3](https://doi.org/10.1016/S0167-7012(03)00131-3) PMID: 14500006
 53. Berger N, Muyldermans G, Dupont Y, Quoilin S. Assessing the sensitivity and representativeness of the Belgian Sentinel Network of Laboratories using test reimbursement data. *Arch Public Health.* 2016;74(1):29. <https://doi.org/10.1186/s13690-016-0145-9> PMID: 27504181
 54. Spuesens EB, Hoogenboezem T, Sluijter M, Hartwig NG, van Rossum AM, Vink C. Macrolide resistance determination and molecular typing of *Mycoplasma pneumoniae* by pyrosequencing. *J Microbiol Methods.* 2010;82(3):214-22. <https://doi.org/10.1016/j.mimet.2010.06.004> PMID: 20547188
 55. Brown RJ, Macfarlane-Smith L, Phillips S, Chalker VJ. Detection of macrolide resistant *Mycoplasma pneumoniae* in England, September 2014 to September 2015. *Euro Surveill.* 2015;20(48):30078. <https://doi.org/10.2807/1560-7917.ES.2015.20.48.30078> PMID: 26675545
 56. Rasmussen JN, Voldstedlund M, Andersen RL, Ellermann-Eriksen S, Jensen TG, Johansen HK, et al. Increased incidence of *Mycoplasma pneumoniae* infections detected by laboratory-based surveillance in Denmark in 2010. *Euro Surveill.* 2010;15(45):19708. <https://doi.org/10.2807/ese.15.45.19708-2010> PMID: 21087593
 57. Hohenthal U, Vainionpää R, Meurman O, Vahtera A, Katiskalahti T, Nikoskelainen J, et al. Aetiological diagnosis of community acquired pneumonia: utility of rapid microbiological methods with respect to disease severity. *Scand J Infect Dis.* 2008;40(2):131-8. <https://doi.org/10.1080/00365540701534525> PMID: 17852937
 58. Kawai Y, Miyashita N, Kubo M, Akaike H, Kato A, Nishizawa Y, et al. Therapeutic efficacy of macrolides, minocycline, and tosylloxacin against macrolide-resistant *Mycoplasma pneumoniae* pneumonia in pediatric patients. *Antimicrob Agents Chemother.* 2013;57(5):2252-8. <https://doi.org/10.1128/AAC.00048-13> PMID: 23459497
 59. Hung HM, Chuang CH, Chen YY, Liao WC, Li SW, Chang IY, et al. Clonal spread of macrolide-resistant *Mycoplasma pneumoniae* sequence type-3 and type-17 with recombination on non-P1 adhesin among children in Taiwan. *Clin Microbiol Infect.* 2021;27(8):1169.e1-6. <https://doi.org/10.1016/j.cmi.2020.09.035> PMID: 33010445
 60. Rodriguez N, Mondeja B, Sardiñas R, Vega D, Dumke R. First detection and characterization of macrolide-resistant *Mycoplasma pneumoniae* strains in Cuba. *Int J Infect Dis.* 2019;80:115-7. <https://doi.org/10.1016/j.ijid.2018.12.018> PMID: 30634044
 61. Dierig A, Hirsch HH, Decker ML, Bielicki JA, Heininger U, Ritz N. *Mycoplasma pneumoniae* detection in children with respiratory tract infections and influence on management - a retrospective cohort study in Switzerland. *Acta Paediatr.* 2020;109(2):375-80. <https://doi.org/10.1111/apa.14891> PMID: 31168877

License, supplementary material and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2022.